

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Grant of Patent Security Interest
CONVEYING PARTY DATA	
Name	Execution Date
Decode Genetics EHF (in Icelandic: Islensk Erfdagreining EHF)	11/12/2009
RECEIVING PARTY DATA	
Name:	Saga Investments LLC
Street Address:	c/o O'Melveny & Myers LLP
Internal Address:	2765 Sand Hill Road
City:	Menlo Park
State/Country:	CALIFORNIA
Postal Code:	94025
PROPERTY NUMBERS Total: 72	
Property Type	Number
Patent Number:	7598397
Patent Number:	7402684
Patent Number:	7576102
Patent Number:	7579483
Patent Number:	7585630
Patent Number:	7507531
Patent Number:	6893828
Patent Number:	7244571
Patent Number:	7435548
Patent Number:	7384736
Patent Number:	7148008
Patent Number:	6319710
Patent Number:	6630304
Patent Number:	7495147

501014223

PATENT
REEL: 023510 FRAME: 0243

CH \$2880.00 7598397

Patent Number:	7404079
Patent Number:	6225093
Patent Number:	6524794
Patent Number:	7016910
Patent Number:	7146375
Patent Number:	7152073
Patent Number:	6970874
Application Number:	11247431
Application Number:	12264053
Application Number:	12136874
Application Number:	11462278
Application Number:	11462263
Application Number:	11832816
Application Number:	11833313
Application Number:	12472958
Application Number:	11748897
Application Number:	11833382
Application Number:	12275163
Application Number:	12275152
Application Number:	12275165
Application Number:	12275164
Application Number:	12275168
Application Number:	61116569
Application Number:	61116572
Application Number:	61228315
Application Number:	12442254
Application Number:	12442233
Application Number:	12302463
Application Number:	12442171
Application Number:	12302473
Application Number:	12302538
Application Number:	11985979
Application Number:	12303328
Application Number:	12139374
Application Number:	11920590

Application Number:	11043752
PCT Number:	US0334681
Application Number:	10976368
Application Number:	10769542
PCT Number:	US0332556
Application Number:	11270804
Application Number:	10769744
Application Number:	10587412
PCT Number:	US0503312
Application Number:	11096191
Application Number:	11913807
Application Number:	11592699
Application Number:	12315114
Application Number:	60423541
Application Number:	10533365
Application Number:	11663231
Application Number:	09946807
Application Number:	10571865
Application Number:	11515368
Application Number:	11185033
Application Number:	61122267
Application Number:	11407458
Application Number:	11912248

CORRESPONDENCE DATA

Fax Number: (415)984-8701
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 415-984-8700
 Email: aechery@omm.com
 Correspondent Name: Jennifer Taylor, Esq.
 Address Line 1: O'Melveny & Myers LLP
 Address Line 2: Two Embarcadero Center, 28th Floor
 Address Line 4: San Francisco, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER:	891776-045
NAME OF SUBMITTER:	Alexandra C. Echery

Total Attachments: 10

PATENT
REEL: 023510 FRAME: 0245

source=Decode Genetics EHF Security Interest#page1.tif
source=Decode Genetics EHF Security Interest#page2.tif
source=Decode Genetics EHF Security Interest#page3.tif
source=Decode Genetics EHF Security Interest#page4.tif
source=Decode Genetics EHF Security Interest#page5.tif
source=Decode Genetics EHF Security Interest#page6.tif
source=Decode Genetics EHF Security Interest#page7.tif
source=Decode Genetics EHF Security Interest#page8.tif
source=Decode Genetics EHF Security Interest#page9.tif
source=Decode Genetics EHF Security Interest#page10.tif

GRANT OF PATENT SECURITY INTEREST

WHEREAS, ISLENSK ERF DAGREINING EHF., a company formed under the laws of Iceland ("**Grantor**"), owns and uses in its business, and will in the future adopt and so use, various intangible assets, including the Patent Collateral (as defined below); and

WHEREAS, deCODE genetics, Inc., a Delaware corporation ("**deCODE**"), MediChem Life Sciences, Inc., a Delaware corporation ("**MediChem**"), Emerald Biostructures, Inc. (formerly deCODE Biostructures, Inc.), a Washington corporation ("**Biostructures**" and, together with deCODE and MediChem, collectively "**Borrowers**" and each, a "**Borrower**"), have issued that certain Secured Promissory Note dated as of September 11, 2009 (said Secured Promissory Note, as it may heretofore have been and as it may hereafter be further amended, restated, supplemented or otherwise modified from time to time, being the "**Secured Note**") in favor of Saga Investments LLC ("**Secured Party**"), which evidences a loan made by Secured Party, subject to the terms and conditions set forth in the Secured Note; and

WHEREAS, Grantor has executed and delivered that certain Guaranty dated as of September 11, 2009 (said Guaranty, as it may heretofore have been and as it may hereafter be further amended, restated, supplemented or otherwise modified from time to time, being the "**Guaranty**") in favor of Secured Party, pursuant to which Grantor has guaranteed the prompt payment and performance when due of all obligations of Borrowers under the Secured Note, including, without limitation, the obligation of Borrower to make payments thereunder in the event of early termination thereof; and

WHEREAS, pursuant to the terms of a Security Agreement dated as of September 11, 2009 (said Security Agreement, as it may heretofore have been and as it may hereafter be further amended, restated, supplemented or otherwise modified from time to time, being the "**Security Agreement**"), among Grantor, Secured Party and the other grantors named therein, Grantor created in favor of Secured Party a security interest in, and Secured Party has become a secured creditor with respect to, the Patent Collateral;

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, subject to the terms and conditions of the Security Agreement, to evidence further the security interest granted by Grantor to Secured Party pursuant to the Security Agreement, Grantor hereby grants to Secured Party a security interest in all of Grantor's right, title and interest in and to the following, in each case whether now or hereafter existing or in which Grantor now has or hereafter acquires an interest and wherever the same may be located (the "**Patent Collateral**");

- (i) all rights, title and interest (including rights acquired pursuant to a license or otherwise) in and to all patents and patent applications and rights and interests in patents and patent applications under any domestic or foreign law that are presently, or in the future may be, owned or held by such Grantor and all patents and patent applications and rights, title and interests in patents and patent applications under any domestic or foreign law that are presently, or in the future may be, owned by such Grantor in whole or in part (including, without limitation, the patents and patent applications set forth on

Schedule A annexed hereto), all rights (but not obligations) corresponding thereto to sue for past, present and future infringements and all re-issues, divisions, continuations, renewals, extensions and continuations-in-part thereof; and

(ii) all proceeds, products, rents and profits of or from any and all of the foregoing Patent Collateral and, to the extent not otherwise included, all payments under insurance (whether or not Secured Party is the loss payee thereof), or any indemnity, warranty or guaranty, payable by reason of loss or damage to or otherwise with respect to any of the foregoing Patent Collateral. For purposes of this Grant of Patent Security Interest, the term "**proceeds**" includes whatever is receivable or received when Patent Collateral or proceeds are sold, licensed, exchanged, collected or otherwise disposed of, whether such disposition is voluntary or involuntary.

Grantor does hereby further acknowledge and affirm that the rights and remedies of Secured Party with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

[The remainder of this page intentionally left blank.]

IN WITNESS WHEREOF, Grantor has caused this Grant of Patent Security Interest to be duly executed and delivered by its officer thereunto duly authorized as of the 12th day of November, 2009.

ISLENSK ERF DAGREINING EHF.

By:

Name: KARI STEFANSSON

Title: CEO

Grant of Patent Security Interest
to Security Agreement

SF1:781050

PATENT
REEL: 023510 FRAME: 0249

**SCHEDULE A
TO
GRANT OF PATENT SECURITY INTEREST**

Patents Issued:

<u>Patent No.</u>	<u>Issue Date</u>	<u>Invention</u>
7598397	10/6/09	Sulfonamide peri-Substituted Bicyclics for Occlusive Artery Disease
7402684	7/22/08	Biaryl Substituted Heterocycle Inhibitors of LTA4H for Treating Inflammation
7576102	8/18/09	Biaryl Substituted Nitrogen Containing Heterocycle Inhibitors of LTA4H for Treating Inflammation
7579483	8/25/09	Process for the Preparation of 7-(Acryloyl) Indoles
7585630	9/8/09	Genetic Variants in the TCF7L2 Gene as Diagnostic Markers for Risk of Type 2 Diabetes Mellitus
7507531	3/24/09	Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
6893828	5/17/05	Methods For Producing Ex Vivo Models for Inflammatory Disease and Uses Thereof
7244571	7/17/07	Methods For Producing Ex Vivo Models for Inflammatory Disease and Uses Thereof
7435548	10/14/08	Methods for Producing Ex Vivo Models for Inflammatory Disease and Uses Thereof
7384736	6/10/08	Methods for Producing Drug Sensitivity in Patients Afflicted With An Inflammatory Disease

7148008	12/12/06	Methods for Predicting Drug Sensitivity in Patients Afflicted With An Inflammatory Disease
6319710	11/20/01	Human Narcolepsy Gene
6630304	10/7/03	Human Osteoporosis Gene
7495147	2/24/09	Neureulin-1 transgenic mouse and methods of use
7404079	7/22/08	Automatic Identity Protection System with Remote Third Party Monitoring
6225093	5/1/01	Detection of C4A Deletion by Long Range PCR
6524794	2/25/03	Identical-By-Descent Fragment Enrichment
7016910	3/21/06	Indexing, Rewriting and Efficient Querying Of Relations Referencing Semistructured Data
7146375	12/5/06	Inference Control Method In A Data Cube
7152073	12/19/06	Method and System for Defining Sets By Querying Relational Data Using A Set Definition Language
6970874	11/29/05	Populating Data Cubes Using Calculated Relations

Patents Pending:

<u>Date Filed</u>	<u>Application Number</u>	<u>Invention</u>
11/10/2005	11/247,431	Carboxylic Acid Peri-Substituted Bicyclics for Occlusive Artery Disease
3/11/08	12/264,053	Aryl Sulonamide Peri-Substituted Bicyclics for Occlusive Artery Disease

11/6/08	12/136,874	Biaryl Substituted Heterocycle Inhibitors of LTA4H for Treating Inflammation
3/8/06	11/462,278	Biaryl Nitrogen-Heterocycle Inhibitors of LTA4H for Treating Inflammation
3/8/06	11,462,263	N-Linked Aryl Heteroaryl Inhibitors of LTA4H for Treating Inflammation
2/8/07	11/832,816	Phenoxymethylalkyne Inhibitors of LTA4H for Treating Inflammation
3/8/07	11/833,313	Pyazolyphenyl and Pyrrolylphenyl Inhibitors of LTA4H for Treating Inflammation
5/27/09	12/472,958	Biaryl Substituted Nitrogen Containing Inhibitors of LTA4H for Treating Inflammation
5/15/07	11/748,897	7-(Acryloyl) Indole Compositions and Methods of Making and Using Same
3/8/07	11/833,382	Arylamino Acid Derivatives as Inhibitors for Treating Inflammation
11/20/08	12/275,163	PDE4 Inhibitors for Treating Inflammatory, Cardiovascular and CNS Disorders
11/20/08	12/275,152	Biaryl PDE4 Inhibitors for Treating Pulmonary and Cardiovascular Disorders
11/20/08	12/275,165	Substituted Benzoazole PDE4 Inhibitors for Treating Inflammatory, Cardiovascular and CNS Disorders
11/20/08	12/275,164	Substituted Benzoazole PDE4 Inhibitors for Treating Pulmonary and Cardiovascular Disorders
11/20/08	12/275,168	4-(OR 5) Substituted Catechol Derivatives

11/20/08	61/116,569	AZA-Bridged Bicyclic Heteroaryl PDE4 Inhibitors for Treating Inflammation
11/20/08	61/116,572	PDE4 Modulators for Treating Inflammation
7/24/09	61/228,315	Process for preparing 4-{{(S)-2-[4-(4- Chlorophenoxy) phoxymethyl]pyrrolidin-1- yl}}butyric acid salts
10/26/07	12/442,254	CANCER SUSCEPTIBILITY VARIANTS ON CHR8Q24.21
11/30/07	12/442,233	Genetic Susceptibility Variants of type 2 Diabetes Mellitus
12/5/07	12/302,463	GENETIC MARKERS FOR RISK MANAGEMENT OF CARDIAC ARRHYTHMIA
2/7/08	12/442,171	Genetic variants contributing to risk of prostrate cancer
3/26/08	12/302,473	Genetic variants as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
2/21/08	12/302,538	GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE
11/19/07	11/985,979	Systems and methods for Personalized medicine using Linkage Analysis
5/21/08	12/303,328	Genetic variants on chr 5p12 and 10q26 as Markers for Use in Breast Cancer risk assessment, diagnosis, prognosis and treatment
6/13/08	12/139,374	Genetic variants on CHR 15q24 as markers for use in diagnosis, prognosis and treatment of pseudoexfoliation syndrome and glaucoma

5/18/06	11/920,590	Variants at Chr8q24.21 Confer Risk of Cancer
1/26/05	11/043,752	Methods of Diagnosis and Treatment for Asthma and other Respiratory Diseases Based On Haplotype Association
4/7/04	PCT/US03/34681	Human Type II Diabetes Gene-KV Channel-Interfacing Protein (KChIP1) Located On Chromosome 5
1/5/05	10/976,368	Human Type II Diabetes Gene-KV Channel-Interfacing Protein (KChIP1) Located On Chromosome 5
1/3/04	10/769,542	Susceptibility Gene for Myocardial Infarction and Stroke
10/16/03	PCT/US03/32556	Susceptibility gene for Myocardial Infarction, Stroke and PAOD; Methods of Treatment
11/9/05	11/270,804	Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
1/30/04	10/769,744	Susceptibility gene for Myocardial Infarction, Stroke and PAOD; Methods of Treatment
1/31/05	10/587,412	Susceptibility gene for Myocardial Infarction, Stroke and PAOD; Methods of Treatment
1/30/05	PCT/US05/03312	Susceptibility gene for Myocardial Infarction, Stroke and PAOD; Methods of Treatment
3/30/05	11/096,191	Susceptibility gene for Myocardial Infarction, Stroke and PAOD; Methods of Treatment
3/30/06	11/913,807	Susceptibility gene for Myocardial Infarction; Stroke and PAOD; Methods of Treatment

11/3/06	11/592,699	Methods for Predicting Drug Sensitivity in Patients Afflicted with An Inflammatory Disease
11/26/08	12/315,114	GENETIC VARIANTS ON CHR 11Q AND 6Q AS MARKERS FOR PROSTATE AND COLORECTAL CANCER PREDISPOSITION
11/1/02	60/423,541	Type II Diabetes Gene Slit-3 Located On Chromosome 5q35
10/31/03	10/533,365	Type II Diabetes Gene Slit-3 Located On Chromosome 5q35
6/6/07	11/663,231	ASSOCIATION OF GENE EXPRESSION AND PSYCHIATRIC DISORDERS
9/5/01	09/946,807	Human Schizophrenia Gene
9/17/04	10/571,865	INVERSION ON CHROMOSOME 8p23 IS RISK FACTOR FOR ANXIETY DISORDERS, DEPRESSION AND BIPOLAR DISORDERS
8/31/06	11/515,368	Methods for Diagnosing and Characterizing Breast Cancer and Susceptibility to Breast Cancer
1/15/04	11/185,033	Method for Diagnosing Osteoporosis or a susceptibility to Osteoporosis based on Haplotype Association
12/12/08	61/122,267	GENETIC VARIANTS AS MARKERS FOR USE IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF EOSINOPHILIA, ASTHMA, AND MYOCARDIAL INFARCTION
4/20/06	11/407,458	Sustained Release Formulation and Dosing Schedules of Leukotriene Synthesis Inhibitor for Human Therapy

4/21/06

11/912,248

Sustained Release Formulation and
Dosing Schedules of Leukotriene
Synthesis Inhibitor for Human
Therapy